A novel class of ZNF384 aberrations in acute leukemia.
Journal
Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425
Informations de publication
Date de publication:
09 11 2021
09 11 2021
Historique:
received:
19
05
2021
accepted:
28
06
2021
pubmed:
17
9
2021
medline:
30
11
2021
entrez:
16
9
2021
Statut:
ppublish
Résumé
Fusion of the ZNF384 gene as the 3' partner to several different 5' partner genes occurs recurrently in B-cell precursor acute lymphoblastic and mixed phenotype B/myeloid leukemia. These canonical fusions (ZNF384r) contain the complete ZNF384 coding sequence and are associated with a specific gene expression signature. Cases with this signature, but without canonical ZNF384 fusions (ZNF384r-like cases), have been described previously. Although some have been shown to harbor ZNF362 fusions, the primary aberrations remain unknown in a major proportion. We studied 3 patients with the ZNF384r signature and unknown primary genetic background and identified a previously unknown class of genetic aberration affecting the last exon of ZNF384 and resulting in disruption of the C-terminal portion of the ZNF384 protein. Importantly, in 2 cases, the ZNF384 aberration, indel, was missed during the bioinformatic analysis but revealed by the manual, targeted reanalysis. Two cases with the novel aberrations had a mixed (B/myeloid) immunophenotype commonly associated with canonical ZNF384 fusions. In conclusion, we present leukemia cases with a novel class of ZNF384 aberrations that phenocopy leukemia with ZNF384r. Therefore, we show that part of the so-called ZNF384r-like cases represent the same genetic subtype as leukemia with canonical ZNF384 fusions.
Identifiants
pubmed: 34529760
pii: 476937
doi: 10.1182/bloodadvances.2021005318
pmc: PMC8579251
doi:
Substances chimiques
Trans-Activators
0
Transcription Factors
0
ZNF384 protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4393-4397Informations de copyright
© 2021 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
Références
Bioinformatics. 2010 Mar 1;26(5):589-95
pubmed: 20080505
Genome Res. 2017 Feb;27(2):185-195
pubmed: 27903646
Nature. 2018 Oct;562(7727):373-379
pubmed: 30209392
Proc Natl Acad Sci U S A. 2018 Dec 11;115(50):E11711-E11720
pubmed: 30487223
Haematologica. 2019 Jul;104(7):1396-1406
pubmed: 30630978
Leukemia. 2021 Nov;35(11):3272-3277
pubmed: 33692463
Leukemia. 2015 Dec;29(12):2445-8
pubmed: 25943178
Nat Genet. 2019 Feb;51(2):296-307
pubmed: 30643249
Haematologica. 2021 Aug 01;106(8):2066-2075
pubmed: 32646889
Genome Res. 2012 Mar;22(3):568-76
pubmed: 22300766
Nat Commun. 2016 Nov 08;7:13331
pubmed: 27824051
Haematologica. 2017 Jan;102(1):118-129
pubmed: 27634205
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
EBioMedicine. 2016 Jun;8:173-183
pubmed: 27428428
Genome Biol. 2011 Aug 11;12(8):R72
pubmed: 21835007
N Engl J Med. 2014 Sep 11;371(11):1005-15
pubmed: 25207766
PLoS Comput Biol. 2011 May;7(5):e1001138
pubmed: 21625565